Cartesian Therapeutics (RNAC) Interest Coverage Ratio (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Interest Coverage Ratio of 22.67 for Q1 2026, up 67.17% year-over-year from 13.56 in Q1 2025, and up 67.28% quarter-over-quarter from 69.29 in Q4 2025.
Cartesian Therapeutics (RNAC) Interest Coverage Ratio (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Interest Coverage Ratio for 12 consecutive years, with 22.67 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 67.17% year-over-year to 22.67; the TTM figure through Mar 2026 stood at 40.75 (down 10241.13% YoY), while the FY2025 annual figure was 0.48, down 172.72% from the prior year.
- Interest Coverage Ratio grew to 22.67 in Q1 2026 per RNAC's latest filing, from 69.29 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 19.38 in Q2 2022 and bottomed at 69.29 in Q4 2025.
- Historically, Interest Coverage Ratio has averaged 13.25 across 5 years, with a median of 4.14 in 2025.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio jumped 2949.22% — and 2024, when it sank 9394.14%.
- Cartesian Therapeutics' Interest Coverage Ratio stood at 5.19 in 2022, then jumped by 94.64% to 0.28 in 2023, then tumbled by 9394.14% to 26.44 in 2024, then slumped by 162.05% to 69.29 in 2025, then soared by 67.28% to 22.67 in 2026.
- Business Quant data shows RNAC's Interest Coverage Ratio at 22.67 in Q1 2026, 69.29 in Q4 2025, and 4.14 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | -2.14 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.14 |
| Mar 31, 2026 | -22.67 |
| Dec 31, 2025 | -69.29 |
| Sep 30, 2025 | -4.14 |
| Jun 30, 2025 | -1.28 |
| Mar 31, 2025 | -69.05 |
| Dec 31, 2024 | -26.44 |
| Sep 30, 2024 | -1.16 |
| Jun 30, 2024 | 0.42 |
| Mar 31, 2024 | -1.05 |
| Dec 31, 2023 | -0.28 |
| Sep 30, 2023 | -10.26 |
| Jun 30, 2023 | -24.78 |
| Mar 31, 2023 | -22.75 |
| Dec 31, 2022 | -5.19 |
| Sep 30, 2022 | -1.99 |
| Jun 30, 2022 | 19.38 |
| Mar 31, 2022 | 15.24 |
| Dec 31, 2021 | -31.13 |
| Sep 30, 2021 | -2.77 |